Active surveillance with selective delayed intervention for favourable risk prostate cancer: Clinical experience and a "number needed to treat" analysis

European Urology, Supplements

Volumn 5, Issue 6, 2006, Pages 479-486

  Klotz, Laurence ^a   Nam, Robert ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Good risk; Prostate cancer; Surveillance; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE;

EID: 33644859600     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.02.014     Document Type: Conference Paper

References (45)

1. W.A. Sakr, G.P. Haas, and B.F. Cassin The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients J Urol 150 1993 379
2. C.C. Boring, T.S. Squires, and T. Tong Cancer statistics, 1993 CA Cancer J Clin 43 1993 7
3. A. Jemal, R.C. Tiwari, and T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8
4. M. McGregor, J.A. Hanley, and J.F. Boivin Screening for prostate cancer: estimating the magnitude of overdetection CMAJ 159 1998 1368
5. R. Etzioni, D.F. Penson, and J.M. Legler Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981
6. P. Albertsen, J.A. Hanley, and J. Fine 20-Year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
7. P.C. Albertsen, J.A. Hanley, and G.H. Barrows Prostate cancer and the Will Rogers phenomenon Natl Cancer Inst 97 2005 1248 1253
8. K.A. Hanash, D.C. Utz, and E.N. Cook Carcinoma of the prostate: a 15 year followup J Urol 107 1972 450
9. J.L. Johansson, and H. Johansson Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden JAMA 277 1997 467
10. S. Lerner, C. Seale-Hacokins, and C.E. Carlton The risk of dying of prostate cancer in patients with clinically localized disease J Urol 146 1991 1040
11. R. Handley, T.W. Carr, and D. Travis Deferred treatment for prostate cancer Br J Urol 62 1998 249
12. J. Adolfsson, J. Carstensen, and T. Lowhagen Deferred treatment in clinically localized prostate carcinoma Br J Urol 69 1992 183
13. G. Waaler, and A.E. Stenwig Prognosis of localised prostatic cancer managed by "watch and wait" policy Br J Urol 72 1993 214 219
14. W.F. Whitmore Jr., I.A. Warner, and I.M. Thompson Jr. Expectant management of localized prostatic cancer Cancer 67 1991 1091
15. N. George Natural history of localised prostatic cancer managed by conservative therapy alone Lancet 1 1988 494
16. G. Aus, I. Hugosson, and L. Norlen Long-term survival and mortality in prostate cancer treated with noncurative intent J Urol 154 1995 460
17. G. Sandblom, and M.D. Varenhorst Long-term survival in a Swedish population-based cohort of men with prostate cancer Urology 56 2000 442
18. C. Parker Active surveillance: towards a new paradigm in the management of early prostate cancer Lancet Oncol 5 2004 101
19. C. Parker Active surveillance: an individualized approach to early prostate cancer BJU Int 92 2003 2
20. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
21. J.C. Presti Jr. Prostate biopsy: how many cores are enough? Urol Oncol 21 2003 135
22. C.R. Pound, A.W. Partin, and M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
23. G. Chodak The management of localized prostate cancer J Urol 152 1994 1766
24. G. Draisma, and F.H. Schroeder Lead times and overdetection due to PSA screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
25. M. Tornblom Lead time associated with screening for prostate cancer Int J Cancer 108 2004 122 129
26. T.A. Stamey, F.S. Freiha, and J.E. McNeal Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 1993 933
27. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
28. J.I. Epstein, G. Pizov, and P.C. Walsh Correlation of pathologic findings with progression after radical retropubic prostatectomy Cancer 71 1993 3582
29. J.I. Epstein, M. Carmichael, and A.W. Partin Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup J Urol 149 1993 1478
30. J.I. Epstein, D.W. Chan, and L.J. Sokoll Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings J Urol 160 1998 2407
31. Y. Goto, M. Ohori, and A. Arakawa Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies J Urol 156 1996 1059
32. H. Augustin, P.G. Hammerer, and M. Graefen Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction Eur Urol 43 2003 455
33. M. Noguchi, T.A. Stamey, and J.E. McNeal Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer J Urol 166 2001 104
34. M.B. Irwin, and J.G. Trapasso Identification of insignificant prostate cancers: analysis of preoperative parameters Urology 44 1994 862 867 discussion 867-8
35. M.R. Cupp, D.G. Bostwick, R.P. Myers, and J.E. Oesterling The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis J Urol 153 1995 1543 1548
36. J.W. Anast, G.L. Andriole, T.A. Bismar, Y. Yan, and P.A. Humphrey Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 64 2004 544 550
37. A. Bill-Axelson, and L. Holmberg Radical prostatectomy versus watchful waiting (update) N Engl J Med 352 2005 1977 1984
38. S. Egawa, Y. Arai, and K. Tobisu Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy Prostate Cancer Prostatic Dis 3 2000 269
39. D.B. McLaren, M. McKenzie, and G. Duncan Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma Cancer 82 1998 342
40. A.V. D'Amico, M.H. Chen, K.A. Roehl, and W.J. Catalona Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
41. R. Choo, L. Klotz, and C. Danjoux Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 167 2002 1664
42. R. Choo, G. DeBoer, and L. Klotz PSA doubling time of prostate carcinoma managed with watchful observation alone Int J Radiat Oncol Biol Phys 50 2001 615
43. T.A. Stamey, M. Caldwell, J.E. McNeal, R. Nolley, M. Hemenez, and J. Downs The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172 2004 1297 1301
44. G. Steineck, F. Helgesen, and J. Adolfsson Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting N Engl J Med 347 2002 790 796
45. J.I. Epstein, P.C. Walsh, and H.B. Carter Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease J Urol 166 2001 1688